Clinical trial NCT06089941: Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
Official title: Prospective Study of Circulating Tumor DNA Sequencing in Peripheral T-cell Lymphomas
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Peripheral T Cell Lymphoma
Keywords: peripheral T Cell Lymphoma
Next generation sequencing
circulating tumor DNA
Low-pass whole genome sequencing
Lead sponsor: Centre Henri Becquerel
Sponsor class: OTHER
First posted: 2023-10-19
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patient with newly or relapse/refractory peripheral T Cell Lymphoma

Brief summary: The purpose of this study is to assess the feasibility of analyzing circulating tumor DNA (ctDNA) as a biomarker using the shallow whole genome sequencing (lpWGS) technique coupled with deep sequencing of a targeted panel of genes (NGS), in a population of patients with newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL).

Detailed description: Peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of diseases resulting from the clonal proliferation of mature post-thymic lymphocytes. These T-cell neoplasms account for approximately 10-15% of all lymphomas and patients with these lymphomas have among the worst 5-year relative survivals (36%-56%, depending on prognostic factors). There are no biomarkers validated in PTCL.

Low pass whole genome sequencing (lpWGS) is an innovative molecular biology technique capable of detecting variations in the number of gene copies in patients' blood, which is a reflection of the quantity of tumor cells in the patient, lymphoma cells carrying numerous gains and deletions of certain genes at the somatic level. lpWGS is inexpensive, requires small quantities of DNA, targets the entire genome, is less time-consuming than other techniques for studying ctDNA and preliminary data in lymphomas have shown the interest of this technique. The investigators hypothesize that this study of ctDNA in PTCL will be relevant, sensitive and very informative for monitoring patients with the lpWGS technique combined with a panel of genes targeted in depth by NGS that the investigators propose to implement. This is a multicenter, prospective study, based on biological samples and clinical and imaging data to be collected.

This study will be offered to each patient suffering from PTCL, including T/NK lymphomas (NKTL) with systemic involvement (excluding cutaneous T-cell lymphomas) having an indication for systemic treatment.

Eligibility criteria: Inclusion Criteria:

* Aged 18 or over
* Newly diagnosed or relapsed/refractory peripheral T-cell lymphoma (PTCL), including T/NK lymphoma (NKTL)
* Pre-therapeutic FDG PET-CT already performed
* Signed informed consent
* Patients affiliated with or beneficiaries of a health insurance plan

Exclusion Criteria:

* Cutaneous T-cell lymphomas without systemic involvement
* Pregnant or breastfeeding women
* For newly diagnosed patients: patient who has already started the first systemic treatment for their lymphoma (apart from pre-phase corticosteroid therapy which is authorized)
* For patients in a relapsed/refractory situation: Patient who has already started the new specific line of lymphoma treatment planned for the current relapsed/refractory situation (apart from pre-phase corticosteroid therapy which is authorized)
* Lack of patient consent
* Patient whose weight is less than 30 kg
* Protected adult or deprived of freedoms (under guardianship or curatorship)
* Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographic problem, etc.).

Primary outcomes:
measure: Feasibility of ctDNA assessement
timeFrame: at the inclusion
measure: Feasibility of ctDNA assessement
timeFrame: 8 weeks
measure: Feasibility of ctDNA assessement
timeFrame: 16 weeks
Secondary outcomes:
measure: Concordance between ctDNA and tumor mutational profile
timeFrame: at the inclusion
measure: Progression free survival
timeFrame: one year
measure: Overal survival
timeFrame: one year
measure: Imaging assessment by PET-CT
timeFrame: 16 weeks
Other outcomes:
Locations:
city: Rouen
country: France
facility: Centre Henri Becquerel
Study officials:
affiliation: Centre Henri Becquerel
name: Vincent Camus
role: PRINCIPAL_INVESTIGATOR
References: